Kyorin Pharmaceutical: Partial revisions to the 66th “Notice of Convocation of the Annual General Meeting of Shareholders”
Kyorin Pharmaceutical: Notice of Convocation of the 66th Annual General Meeting of Shareholders and Shareholders' Meeting Materials (Revised Edition)
Kyorin Pharmaceutical: Notice of the 66th Annual General Meeting of Shareholders
Kyorin Pharmaceutical: Notice of Convocation of the 66th Annual General Meeting of Shareholders and Shareholders' Meeting Materials
Kyorin Pharmaceutical: Notice regarding dividends from surplus funds
Kyorin Pharmaceutical: Notice regarding changes in officers of Kyorin Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Kyorin Pharmaceutical: Supplemental Financial Results for the Fiscal Year Ending March 2024
Kyorin Pharmaceutical: Date of commencement of operations due to the relocation of the head office
Kyorin Pharmaceutical: Release of the expectorant “Mucodyne Release Tablet Pro 500” by Shionogi Healthcare Co., Ltd.
Kyorin Pharmaceutical: Report on Corporate Governance 2024/02/26
Kyorin Pharmaceutical: Notice regarding changes in officers of our subsidiary: Kyorin Pharmaceutical Group Factory Co., Ltd.
Kyorin Pharmaceutical: Notice regarding changes in officers of our subsidiary: Kyorin Remedio Co., Ltd.
Kyorin Pharmaceutical: Regular personnel changes at Kyorin Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical: Change Report
Kyorin Pharmaceutical: Change Report
Kyorin Pharmaceutical: Change Report
Kyorin Pharmaceutical: Confirmation
KYORIN PHARMACEUTICAL: Quarterly Report - 66th Quarter (2023/10/01 - 2023/12/31)
Kyorin Pharmaceutical: Summary of Financial Results for the 3rd Quarter Ending March 31, 2024 [Japanese GAAP] (Consolidated)
No Data